Survival and treatment of stage IV renal cell carcinoma in academic vs non-academic medical centers

Table 3 Treatment characteristics of patients with metastatic renal cell carcinoma, n (%)

Variable (n = 1068)	Academic (n = 30780)	Non-academic (n = 48587)	P value
Definitive surgical procedure, days from Dx [mean (SD)]	43.1 (63.7)	37.5 (61.5)	< 0.05
Systemic therapy initiated, days from Dx [mean (SD)]	64.5 (57.1)	55.8 (54.2)	< 0.05
Chemotherapy initiated, days from Dx [mean (SD)]	64.9 (61.3)	56.2 (54.9)	< 0.05
Radiation therapy initiated, days from Dx [mean (SD)]	56.1 (76.8)	45.8 (61.6)	< 0.05
Immunotherapy initiated, days from Dx [mean (SD)]	75.6 (65.9)	67.5 (72.9)	< 0.05
Surgical inpatient stay [mean (SD)]	5.64 (7.46)	5.40 (6.92)	0.006
Surgery of primary site			< 0.05
Subtotal nephrectomy	624 (2.0)	612 (1.3)
Complete nephrectomy	876 (2.8)	1417 (2.9)
Radical nephrectomy	11,419 (37.1)	13382 (27.5)
Surgery, other	1,015 (3.3)	1052 (2.2)
Surgery of primary site not performed	16,846 (54.7)	32124 (66.1)
Adjuvant therapy			< 0.05
Adjuvant chemoradiation	65 (0.2)	190 (0.4)
Adjuvant radiation	412 (1.3)	514 (1.1)
Adjuvant chemotherapy	1350 (4.4)	1779 (3.7)
No adjuvant therapy	28953 (94.1)	46104 (94.9)
Immunotherapy			< 0.05
Received immunotherapy	5264 (17.1)	6864 (14.1)
Did not receive immunotherapy	25132 (81.7)	41075 (84.5)
Unknown if received immunotherapy	384 (1.2)	648 (1.3)